Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of decitabine in treating
patients with metastatic or unresectable refractory solid tumors or lymphomas. Drugs used in
chemotherapy, such as decitabine, work in different ways to stop cancer cells from dividing
so they stop growing or die